Statement on FDA Patient Safety Communication

July 13, 2011

Washington, DC -- In a response today, The American College of Obstetricians and Gynecologists (The College) applauds the US Food and Drug Administration's (FDA) effort in protecting women's health by issuing an update to the serious safety and effectiveness concerns related to transvaginal placement of surgical mesh to repair pelvic organ prolapse. The College shares the FDA's concerns and encourages patients and physicians to review the FDA's White Paper that describes, in detail, the health risks associated with the surgical mesh products when used to treat pelvic organ prolapse.

The American College of Obstetricians and Gynecologists (The College), a 501(c)(3) organization, is the nation's leading group of physicians providing health care for women. As a private, voluntary, nonprofit membership organization of approximately 55,000 members, The College strongly advocates for quality health care for women, maintains the highest standards of clinical practice and continuing education of its members, promotes patient education, and increases awareness among its members and the public of the changing issues facing women's health care. The American Congress of Obstetricians and Gynecologists (ACOG), a 501(c)(6) organization, is its companion organization.

Follow us on Twitter        Check us out on YouTube